TP53 mutations in head and neck cancer
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Head and neck squamous cell carcinomas (HNSCCs) arising in the mucosal linings of the upper aerodigestive tract are highly heterogeneous, aggressive, and multifactorial tumors affecting more than half a million patients worldwide each year. Classical etiological factors for HNSCC include alcohol, tobacco, and human papillomavirus (HPV) infection. Current treatment options for HNSCCs encompass surgery, radiotherapy, chemotherapy, or combinatorial remedies. Comprehensive integrative genomic analysis of HNSCC has identified mutations in TP53 gene as the most frequent of all somatic genomic alterations. TP53 mutations are associated with either loss of wild‐type p53 function or gain of functions that promote invasion, metastasis, genomic instability, and cancer cell proliferation. Interestingly, disruptive TP53 mutations in tumor DNA are associated with aggressiveness and reduced survival after surgical treatment of HNSCC. This review summarizes the current evidence and impact of TP53 mutations in HNSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Cancer Genome Atlas and other recent studies considering the impact of mutations on the progress and inhibition of HNSCC have provided valuable insights into the molecular pathophysiology of HNSCC development and the response to therapy.”
From The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies (2025) · cites this paper as [8]
In the citing paper
“There have been several attempts to categorize mutations based on their impact on causing variations in interactions that could alter protein structure, and these effects could be used to determine their value as prognostic variables. However, these efforts may have limited results due to the diversity of TP53 mutations associated with HNSCC [8].”
From The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies (2025) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“Beyond exerting dominant repression over the wild‐type counterpart due to loss of heterozygosity, some mutants might exert new malignant abilities distinct from those caused by the loss of the wild‐type function.(25,26) Most TP53 missense mutants acquire oncogenic gain‐of‐function (GOF) activities.”
BackgroundTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Since then, multiple genomic sequencing analyses and The Cancer Genome Atlas (TCGA) have established further evidence for deleterious effects of the TP53 gene in HNSCC tumorigenesis and progression(16,17) It is well established that p53 – the translated protein encoded by TP53, called “the guardian of the genome” play…”
Backgroundp53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650 · cited 1×
“metabolism by modulating glycolysis and mitochondrial oxidative phosphorylation system (OXPHOS).(34) HNSCC meets their high metabolic demands via anaerobic glycolysis that helps cancer cells in”
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 1×
“teins display higher oncogenic potential, poor prognosis, poor response to chemotherapy, and accelerated tumor recurrence compared to patients with p53 null tumors.(8,9) In this review, we”
BackgroundWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“TP53 missense mutations can be either DNA contact mutations (R248Q/ R273H) that directly occur at the amino acids mediating p53‐DNA interaction or conformational mutations that indirectly disrupt p53‐ DNA interaction by inducing local (R249S and G245S) or global (R175H and R282W) conformational changes due to the redu…”
BackgroundGain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“PRIMA‐1/APR‐246 successfully completed phase 1/2 clinical trials in patients with hematological malignancies or prostate cancer that included mutant p53 patients.(53) PRIMA‐1 also induces apoptosis and enhances the cytotoxicity of standard chemotherapy in HNSCC cells.”
MethodA Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341 · cited 2×
“For example, Soragni et al.(50) demonstrated using a cell‐penetrating peptide ReACp53 to rescue p53 function in cancer cell lines.”
BackgroundLinks between mutant p53 and genomic instability
Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216 · cited 1×
“dition, mutant TP53 can also alter the DNA replication process and induce genomic instability.(31)”
Background
Research works printed but not linked: 44
- 10.3322/caac.21332 · DOI · Paper page
- Blot WJ, 1988, Smoking and drinking in relation to oral and pharyngeal cancer, Cancer Res, 48, 3282
- 10.1371/journal.pone.0113385 · DOI · Paper page
- Centers for Disease Control and Prevention (CDC), 2012, Human papillomavirus‐associated cancers ‐ United States, 2004‐2008, MMWR Morb Mortal Wkly Rep, 61, 258
- 10.1016/j.oraloncology.2013.12.019 · doi:10.1016/j.oraloncology.2013.12.019
- 10.1177/0194599814538605 · doi:10.1177/0194599814538605
- 10.1038/nature14129 · DOI · Paper page
- 10.1038/nature12634 · DOI · Paper page
- 10.3389/fgene.2021.680699 · doi:10.3389/fgene.2021.680699
- 10.1001/archotol.1997.01900060047008 · doi:10.1001/archotol.1997.01900060047008
- 10.1056/NEJM199106133242402 · DOI · Paper page
- 10.1056/NEJMoa073770 · DOI · Paper page
- 10.1007/s00439-014-1470-0 · DOI
- 10.1002/lary.25915 · DOI
- 10.1038/cgt.2010.63 · DOI · Paper page
- 10.1016/0092-8674(93)90384-3 · DOI · Paper page
- 10.1056/NEJMra0707975 · DOI · Paper page
- 10.1126/science.1905840 · DOI · Paper page
- 10.1158/0008-5472.CAN-14-2735 · DOI · Paper page
- 10.1038/nrc864 · DOI · Paper page
- 10.1158/1078-0432.CCR-11-0046 · DOI
- 10.1158/0008-5472.CAN-14-2729 · DOI
- 10.4161/23723548.2014.963441 · DOI
- 10.1038/ncb1571 · DOI · Paper page
- 10.1038/s41388-017-0032-z · DOI · Paper page
- 10.1371/journal.pone.0104821 · DOI
- 10.1002/cncr.26321 · DOI
- 10.1177/0022034512467352 · DOI · Paper page
- 10.1038/s41598-020-60707-x · DOI
- 10.1016/j.oraloncology.2015.07.006 · DOI
- 10.1016/j.csbj.2019.07.009 · DOI · Paper page
- Lahin AEB, 2019, Expression of P53 and prognosis in patients with head and neck squamous cell carcinoma (HNSCC), Int J Cancer Clin Res, 6
- Hoffmann TK, 2002, Frequencies of tetramer+ T cells specific for the wild‐type sequence p53(264‐272) peptide in the circulation of patients with head and neck cancer, Cancer Res, 62, 3521
- 10.1158/1078-0432.CCR-07-0682 · DOI
- 10.1002/hed.24406 · DOI · Paper page
- 10.1158/1078-0432.CCR-11-2260 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-1402 · DOI · Paper page
- Bueter M, 2006, Influence of p53 on anti‐tumor immunity (review), Int J Oncol, 28, 519
- 10.1038/s41388-020-1250-3 · DOI · Paper page
- 10.1016/j.celrep.2013.04.012 · DOI · Paper page
- 10.1038/sj.onc.1210294 · DOI · Paper page
- 10.1038/sj.bjc.6605335 · DOI · Paper page
- 10.3389/fonc.2015.00288 · DOI · Paper page
- 10.1016/j.oraloncology.2010.10.011 · DOI · Paper page
Cited by
Mahmoud, A. A., Raih, M. F., Sage, E. E., Ali, Q. M., Suliman, O. H., Ibrahim, S. A. E., Mohamed, O., Abdelrazeg, S., & Mohamed, S. B. (2025) · PLOS One · doi:10.1371/journal.pone.0307859 · Cited by 4
Metadata
- Authors
- Nathan, C., Khandelwal, A. R., Wolf, G. T., Rodrigo, J. P., Mäkitie, A. A., Saba, N. F., Forastiere, A. A., Bradford, C. R., & Ferlito, A.
- Affiliations
- Department of Otolaryngology‐Head and Neck Surgery Louisiana State University‐Health Shreveport Shreveport Louisiana USA
- Department of Otolaryngology‐Head and Neck Surgery University of Michigan Health System Ann Arbor Michigan USA
- Department of Otorhinolaryngology‐Head and Neck Surgery Hospital Universitario Central de Asturias Oviedo Spain
- Department of Otorhinolaryngology‐Head and Neck Surgery University of Helsinki and HUS Helsinki University Hospital Helsinki Finland
- Department of Hematology and Medical Oncology Emory University Atlanta Georgia USA
- Department of Oncology Johns Hopkins University School of Medicine Baltimore Maryland USA
- Department of Otolaryngology‐Head and Neck Surgery The Ohio State University Wexner Medical Center Columbus Ohio USA
- International Head and Neck Scientific Group Padua Italy
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 2022-02-23
- Volume
- 61
- Issue
- 4
- Pages
- 385-391
- ISSN
- 0899-1987
- 1098-2744
- Cited by
- 46
- References
- 10
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.